Nautilus Biotechnology, Inc. (NAUT)
| Market Cap | 299.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.68M |
| Shares Out | 125.10M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,264 |
| Open | 2.310 |
| Previous Close | 2.340 |
| Day's Range | 2.310 - 2.440 |
| 52-Week Range | 2.160 - 4.650 |
| Beta | 1.00 |
| Analysts | Hold |
| Price Target | 6.00 (+147.93%) |
| Earnings Date | Apr 30, 2024 |
About NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affin... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NAUT stock is "Hold" and the 12-month stock price forecast is $6.0.
News
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report...
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
Society award recognizes Dr. Mallick's decades of innovative leadership and science advancing the field of computational proteomics Society award recognizes Dr. Mallick's decades of innovative leaders...
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Former Quantapore founder...
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology to Participate in Upcoming August Investor Conferences
SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology Reports Second Quarter 2023 Financial Results
SEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financia...
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will...
Nautilus Biotechnology Reports First Quarter 2023 Financial Results
SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial result...
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report...
Nautilus Biotechnology to Participate in B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wi...
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results
SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology Expands to San Diego
Proteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential of the proteome Proteomics company opens new office in Southe...
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus' next-generation proteome analysis platform to advance the study of a rare childhood cancer Collaboration ...
Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs
Sujal Patel has been here before. He weathered the 2009 recession as CEO of Isilon Systems, coming out the other end to sell his company the next year for $2.25 billion.
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results
SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit
SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, t...
Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
Representatives of company developing platform for comprehensively quantifying the proteome to provide HUPO leadership with input on technology and product innovation Representatives of company develo...
Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, to...